



FDA Approved New Molecular Entities (NMEs)

January 2022




daridorexant (Quviviq)

dual OX1/OX2 blocker
for insomnia
oral: 25 or 50 mg



Cibirgo (abrocitinib)

JAK1-selective inhibitor
for refractory AD
oral: 100 or 200 mg QD



Kimmtrak (tebentafusp)

gp100-HLA/CD3 bispecific (BITE)
for met. uveal melanoma
injectable



Vabysmo/faricimab

VEGF/Ang-2 bispecific inhibitor
ophthamology (nAMD + DME)
injectable

**drug
hunter**

drughunter.com